CD274 and neoplasm: A survival benefit on third-line or subsequent therapy using a different anti-PD-1 antibody, nivolumab (nivo) in an Asian patient population has also been reported; notably, this was independent of the expression of the PD-1 ligand PD-L1 by the tumor in the ATTRACTION-2 trial [5].